AR and neoplasm: A subset of tumor cells from CRPC patients receiving ADT or current AR pathway inhibition (ARPI) therapy may progress to an AR-negative phenotype, and this is considered to result from an accumulation of neuroendocrine (NE) and stem cell characteristics [4].